This biotechnology firm develops therapeutic modalities using designer sponge RNA technology. Their platform targets disease-causing microRNAs to restore cellular balance, offering a versatile toolbox for treating various diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are caused or exacerbated by imbalances in cellular microRNA (miRNA) levels. Traditional therapeutic approaches often lack the precision to selectively target and modulate these disease-causing miRNAs without affecting other essential cellular processes. This can lead to off-target effects and limited efficacy.
Solution
Ephyra is developing designer sponge RNAs, a novel class of therapeutics engineered to selectively bind and neutralize disease-causing microRNAs (miRNAs), restoring cellular homeostasis. The company's proprietary platform enables the design of sponge RNAs that act as miRNA inhibitors, preventing the targeted miRNAs from interacting with their messenger RNA (mRNA) targets. This approach offers a versatile and precise method for modulating gene expression and treating diseases driven by miRNA dysregulation. The platform's modular design allows for rapid development of new therapies targeting different miRNAs across a range of therapeutic areas.
Target Audience
Ephyra's primary target audience includes pharmaceutical companies and research institutions focused on developing novel RNA-based therapeutics for diseases driven by microRNA dysregulation.
Features
- Designer sponge RNAs engineered for high affinity and specificity to target miRNAs
- Modular platform enabling rapid design and optimization of new sponge RNA therapeutics
- Tunable architecture to accommodate multiple miRNA targets simultaneously
- Potential for systemic delivery and tissue-specific targeting
- Mechanism of action focused on restoring cellular balance by neutralizing disease-causing miRNAs